Related Experiment Video
Updated: Mar 7, 2026

10:41
A Tuberculosis Molecular Bacterial Load Assay TB-MBLA
Published on: April 30, 2020
14.9K
Integrating tuberculosis screening in Kenyan Prevention of Mother-To-Child Transmission programs
L M Cranmer1, A Langat2, K Ronen3
1Emory University School of Medicine and Children's Hospital of Atlanta, Atlanta, Georgia, USA.
Summary
Tuberculosis (TB) screening in Prevention of Mother-To-Child Transmission (PMTCT) programs identified a high rate of positive TB symptom screens among HIV-infected mothers. This screening is crucial for improving maternal and infant health outcomes.
Area of Science:
- Public Health
- Infectious Disease Epidemiology
- Maternal and Child Health
Background:
- Tuberculosis (TB) screening is vital within Prevention of Mother-To-Child Transmission (PMTCT) programs to enhance TB detection, prevention, and treatment.
- Integrating TB screening into PMTCT services is a key strategy for improving health outcomes for mothers and infants.
Purpose of the Study:
- To evaluate the effectiveness of TB screening in a national PMTCT program in Kenya.
- To determine the association between maternal TB symptom screen results and infant cofactors, including HIV infection and TB symptoms.
Main Methods:
- Mother-infant pairs were enrolled at 141 clinics across Kenya during a national PMTCT program evaluation.
- The World Health Organization (WHO) TB symptom screen was administered to 498 HIV-infected mothers.
- Statistical analyses were performed to identify associations between maternal TB symptoms and infant characteristics.
Main Results:
- 33% of HIV-infected mothers screened positive for TB symptoms.
- Positive maternal TB symptom screens were significantly associated with prior TB diagnosis (P = 0.04).
- Mothers with positive TB screens were more likely to have infants with HIV infection (P = 0.02) and non-specific TB symptoms like cough and fever.
Conclusions:
- Postpartum HIV-infected mothers frequently exhibit symptoms suggestive of TB.
- Maternal TB screening in PMTCT programs can identify mothers at higher risk for TB and those with infants showing concerning symptoms.
- Integrating TB screening and prevention into PMTCT programs holds potential for improved maternal and infant health outcomes.
Related Concept Videos
Pulmonary Tuberculosis V
718
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
718
Pulmonary Tuberculosis IV
588
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
588
Pulmonary Tuberculosis I
1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Pulmonary Tuberculosis II
1.8K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.8K
Pulmonary Tuberculosis III
1.2K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
1.2K
Therapeutic Drug Monitoring: Affecting Factors
300
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
300

